JP2012509071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509071A5 JP2012509071A5 JP2011536741A JP2011536741A JP2012509071A5 JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5 JP 2011536741 A JP2011536741 A JP 2011536741A JP 2011536741 A JP2011536741 A JP 2011536741A JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- invariant chain
- protein
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801638 | 2008-11-21 | ||
| DKPA200801638 | 2008-11-21 | ||
| PCT/DK2009/050310 WO2010057501A1 (en) | 2008-11-21 | 2009-11-20 | Priming of an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226711A Division JP2015061530A (ja) | 2008-11-21 | 2014-11-07 | 免疫応答のプライミング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509071A JP2012509071A (ja) | 2012-04-19 |
| JP2012509071A5 true JP2012509071A5 (enExample) | 2013-01-24 |
Family
ID=40823418
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536741A Pending JP2012509071A (ja) | 2008-11-21 | 2009-11-20 | 免疫応答のプライミング |
| JP2014226711A Pending JP2015061530A (ja) | 2008-11-21 | 2014-11-07 | 免疫応答のプライミング |
| JP2017011749A Pending JP2017131220A (ja) | 2008-11-21 | 2017-01-26 | 免疫応答のプライミング |
| JP2019091809A Active JP6825036B2 (ja) | 2008-11-21 | 2019-05-15 | 免疫応答のプライミング |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226711A Pending JP2015061530A (ja) | 2008-11-21 | 2014-11-07 | 免疫応答のプライミング |
| JP2017011749A Pending JP2017131220A (ja) | 2008-11-21 | 2017-01-26 | 免疫応答のプライミング |
| JP2019091809A Active JP6825036B2 (ja) | 2008-11-21 | 2019-05-15 | 免疫応答のプライミング |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20110293704A1 (enExample) |
| EP (3) | EP2355842A1 (enExample) |
| JP (4) | JP2012509071A (enExample) |
| CN (3) | CN102292102A (enExample) |
| AU (1) | AU2009317691A1 (enExample) |
| BR (1) | BRPI0921927B8 (enExample) |
| CA (1) | CA2743229A1 (enExample) |
| CY (1) | CY1122117T1 (enExample) |
| DK (1) | DK2865387T3 (enExample) |
| ES (1) | ES2743677T3 (enExample) |
| HK (1) | HK1209645A1 (enExample) |
| HR (1) | HRP20191594T1 (enExample) |
| HU (1) | HUE045093T2 (enExample) |
| IL (4) | IL212914A0 (enExample) |
| LT (1) | LT2865387T (enExample) |
| PL (1) | PL2865387T3 (enExample) |
| PT (1) | PT2865387T (enExample) |
| RU (2) | RU2011125306A (enExample) |
| SI (1) | SI2865387T1 (enExample) |
| WO (1) | WO2010057501A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3000487B8 (en) | 2007-02-19 | 2022-06-15 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| EP2575877B1 (en) * | 2010-06-04 | 2016-10-19 | INSERM - Institut National de la Santé et de la Recherche Médicale | Novel immunoadjuvant compounds and uses thereof |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| AU2012349855B2 (en) | 2011-12-07 | 2017-12-07 | Belgian Volition Sprl | Method for detecting nucleosome adducts |
| EP2877205A4 (en) * | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| AU2014228489B2 (en) | 2013-03-15 | 2018-11-15 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| KR20160125361A (ko) * | 2013-12-27 | 2016-10-31 | 자임워크스 인코포레이티드 | Ｖａｒ２ｃｓａ－약물 접합체 |
| DK3086815T3 (da) | 2013-12-27 | 2022-05-23 | Zymeworks Inc | Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater |
| RU2723651C2 (ru) | 2014-09-17 | 2020-06-17 | Займворкс Инк. | Цитотоксические и антимитотические соединения и способы их применения |
| WO2017025782A1 (en) | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
| KR20180083327A (ko) | 2015-10-12 | 2018-07-20 | 난토믹스, 엘엘씨 | 바이러스성 암 네오에피토프를 위한 조성물 및 방법 |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| CN109863169A (zh) * | 2016-08-23 | 2019-06-07 | 葛兰素史密丝克莱恩生物有限公司 | 具有连接至不变链(cd74)的短片段的抗原的融合肽 |
| EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| EP3651798A1 (en) * | 2017-07-12 | 2020-05-20 | Nouscom AG | Neoantigen vaccine composition for treatment of cancer |
| ES3029080T3 (en) | 2017-10-10 | 2025-06-23 | Seattle Project Corp | Neoantigen identification using hotspots |
| AU2018358019B2 (en) * | 2017-11-03 | 2023-05-11 | Nouscom Ag | Vaccine T cell enhancer |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| CN108285885A (zh) * | 2017-12-28 | 2018-07-17 | 中国农业大学 | 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用 |
| BR112020024285A2 (pt) | 2018-06-12 | 2021-03-02 | Glaxosmithkline Biologicals S.A. | polinucleotídeos e polipeptídeos de adenovírus |
| BR112021003499A2 (pt) | 2018-10-19 | 2021-05-18 | Nouscom Ag | polipeptídeo, polinucleotídeo, vetor, coleção de dois ou mais vetores, composição farmacêutica e kit |
| WO2020128012A1 (en) | 2018-12-21 | 2020-06-25 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
| RU2725493C2 (ru) * | 2018-12-28 | 2020-07-02 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора |
| WO2020178359A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
| CN111729093B (zh) * | 2020-06-29 | 2022-05-24 | 南京超维景生物科技有限公司 | 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法 |
| EP4137153A1 (en) | 2021-08-18 | 2023-02-22 | Sirion Biotech GmbH | Therapeutic papilloma virus vaccines |
| CN120456919A (zh) | 2022-12-19 | 2025-08-08 | 葛兰素史克生物有限公司 | 乙型肝炎组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US587673A (en) | 1897-08-03 | higgins | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| JP2682061B2 (ja) | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
| US5559028A (en) * | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
| US5876735A (en) | 1994-04-22 | 1999-03-02 | Corixa Corporation | Methods for enhancement of protective immune responses |
| AU7690896A (en) * | 1995-09-14 | 1997-04-01 | Universitat Tubingen | Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide |
| WO1997049430A1 (en) * | 1996-06-26 | 1997-12-31 | Antigen Express, Inc. | Immunotherapy by modulation of antigen presentation |
| CA2685270C (en) * | 1998-05-13 | 2014-07-29 | Pharmexa Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
| US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| SI1957528T1 (sl) * | 2005-11-30 | 2013-02-28 | University Of Copenhagen | Nukleotidno cepivo |
| US20080095798A1 (en) * | 2006-10-18 | 2008-04-24 | Robert Humphreys | Ii-key enhanced vaccine potency |
| US9085638B2 (en) * | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| CA2731444A1 (en) * | 2008-09-02 | 2010-03-11 | Antigen Express, Inc. | Human papillomavirus / li-key hybrids and methods of use |
-
2009
- 2009-11-20 CN CN2009801549244A patent/CN102292102A/zh active Pending
- 2009-11-20 ES ES15152408T patent/ES2743677T3/es active Active
- 2009-11-20 WO PCT/DK2009/050310 patent/WO2010057501A1/en not_active Ceased
- 2009-11-20 CA CA2743229A patent/CA2743229A1/en active Pending
- 2009-11-20 EP EP09760468A patent/EP2355842A1/en not_active Withdrawn
- 2009-11-20 US US13/129,857 patent/US20110293704A1/en not_active Abandoned
- 2009-11-20 CN CN201410485599.2A patent/CN104404068A/zh active Pending
- 2009-11-20 EP EP15152408.9A patent/EP2865387B1/en active Active
- 2009-11-20 BR BRPI0921927A patent/BRPI0921927B8/pt active Search and Examination
- 2009-11-20 PT PT15152408T patent/PT2865387T/pt unknown
- 2009-11-20 RU RU2011125306/10A patent/RU2011125306A/ru unknown
- 2009-11-20 DK DK15152408.9T patent/DK2865387T3/da active
- 2009-11-20 RU RU2017138373A patent/RU2017138373A/ru not_active Application Discontinuation
- 2009-11-20 SI SI200931996T patent/SI2865387T1/sl unknown
- 2009-11-20 PL PL15152408T patent/PL2865387T3/pl unknown
- 2009-11-20 EP EP19173464.9A patent/EP3552622A3/en active Pending
- 2009-11-20 LT LTEP15152408.9T patent/LT2865387T/lt unknown
- 2009-11-20 AU AU2009317691A patent/AU2009317691A1/en not_active Abandoned
- 2009-11-20 JP JP2011536741A patent/JP2012509071A/ja active Pending
- 2009-11-20 HU HUE15152408A patent/HUE045093T2/hu unknown
- 2009-11-20 CN CN201710007117.6A patent/CN107090472A/zh active Pending
-
2011
- 2011-05-16 IL IL212914A patent/IL212914A0/en unknown
-
2014
- 2014-06-16 IL IL233175A patent/IL233175A0/en unknown
- 2014-06-16 IL IL233176A patent/IL233176A0/en unknown
- 2014-06-16 IL IL233174A patent/IL233174A0/en unknown
- 2014-09-10 US US14/482,452 patent/US20150056227A1/en not_active Abandoned
- 2014-11-07 JP JP2014226711A patent/JP2015061530A/ja active Pending
-
2015
- 2015-10-28 HK HK15110589.9A patent/HK1209645A1/en unknown
-
2017
- 2017-01-26 JP JP2017011749A patent/JP2017131220A/ja active Pending
- 2017-04-25 US US15/496,045 patent/US20170290898A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019091809A patent/JP6825036B2/ja active Active
- 2019-09-02 CY CY20191100920T patent/CY1122117T1/el unknown
- 2019-09-04 HR HRP20191594 patent/HRP20191594T1/hr unknown
-
2021
- 2021-06-17 US US17/350,971 patent/US20210386842A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509071A5 (enExample) | ||
| RU2011125306A (ru) | Праймирование иммунного ответа | |
| Yang et al. | Cell-penetrating peptides: efficient vectors for vaccine delivery | |
| JP6321261B2 (ja) | ワクチン組成物及びその使用方法 | |
| An et al. | Silica nanoparticle as a lymph node targeting platform for vaccine delivery | |
| RU2712743C2 (ru) | Вакцина против бешенства | |
| Li et al. | Rational design of T-cell-and B-cell-based therapeutic cancer vaccines | |
| CA3036742A1 (en) | Modified vsv-g and vaccines thereof | |
| AU2016379413A1 (en) | Covalent polymer-antigen conjugated particles | |
| Wang et al. | Cell penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination | |
| JP2013532971A5 (enExample) | ||
| US20040033585A1 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| Bolhassani et al. | DNA immunization as an efficient strategy for vaccination | |
| Jiang | Cell-penetrating peptide-mediated nanovaccine delivery | |
| AU2021307553A1 (en) | APC targeting units for immunotherapy | |
| Wang et al. | Advances of nanotechnology toward vaccine development against animal infectious diseases | |
| CN104136039A (zh) | 靶向交叉呈递的树突状细胞的疫苗体 | |
| US20240207385A1 (en) | Compositions comprising self-assembling vaccines and methods of using the same | |
| JPWO2013147232A1 (ja) | 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル | |
| Bae et al. | Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery | |
| JP5901084B2 (ja) | ペプチドアジュバント | |
| CN118576725A (zh) | 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用 | |
| WO2005091753A2 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| US20050282263A1 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| CN103747799A (zh) | 细胞毒性t细胞诱导剂 |